Clinical Trials Logo

Clinical Trial Summary

This is a clinical trial to evaluate the use of peritumoral injection of near-infrared dye indocyanine green to identify lung lesions and sentinel lymph nodes. The primary purpose is to determine if the use of ICG injected via navigational bronchoscopy, CT-guided or transthoracic allows us to identify the first lymph node that drains from the tumor, and thus would be the most likely site for metastatic disease, and remove it for analysis to improve the ability to detect tumor in this node and to remove this additional site that potentially contains tumor cells. Using this intraoperative imaging technique, we aim to improve the identification of lung nodules for resection and the intraoperative identification of sentinel lymph nodes in the event that a lymphadenectomy is performed.


Clinical Trial Description

Patients enrolled in the study will undergo peritumoral injection of near-infrared dye indocyanine green around the lung lesion or within the adjacent segmental bronchus at the time of surgery. ICG injection will be carried out via navigational bronchoscopy, CT-guided or trans-thoracic ICG injection (dependent on lesion location) and ICG imaging of the sentinel lymph nodes will be undertaken using an NIR-enabled camera. - This study is designed primarily to determine the safety and feasibility of intra-operative localization of thoracic lesions following ICG injection, and second, to include an assessment of the predictive value of sentinel lymph nodes relative to the disease status of the greater lymphadenectomy specimen as well as disease recurrence rates. - We are using a dose approximately 100 times lower than previously approved for injection in the blood. After a few minutes, the surgeon will look at these lymph nodes with near-infrared fluorescence and then remove any fluorescent and non-fluorescent lymph nodes near the tumor, as is standard for lung surgery. - The "filtered" near-infrared light causes the indocyanine green dye to fluoresce so that the surgeon can identify the lymph nodes most likely to contain tumor cells. If the lymph node is not found in the group of nodes usually removed, we will use the near-infrared light to look near the tumor for the sentinel lymph nodes and guide the surgeon so that the sentinel nodes can be removed and studied. The surgeon will then continue with the operation and remove the tumor. The lymph nodes are processed for special analysis tailored to finding metastasis in sentinel lymph nodes. - As is standard of care, patients will be monitored for evidence of recurrence by their surgeon. Recurrences will be recorded. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT03097575
Study type Interventional
Source Massachusetts General Hospital
Contact Yolonda Colson, MD, PhD
Phone 617-726-5200
Email ycolson@partners.org
Status Recruiting
Phase Phase 1/Phase 2
Start date January 6, 2015
Completion date January 1, 2023

See also
  Status Clinical Trial Phase
Recruiting NCT05437380 - Peritumoral Microbubbles and CEUS for SLN Detection and Biopsy in HNSCC N/A
Active, not recruiting NCT04303715 - No Axillary sUrgical Treatment In Clinically Lymph Node Negative Patients After UltraSonography N/A
Completed NCT05498051 - Fluorescent Sentinel Lymph Node Identification in Colon Carcinoma Using Submucosal Bevacizumab-800CW. N/A
Active, not recruiting NCT06169787 - Sentinel Lymph Nodes Biopsy in Cervical Cancer
Completed NCT03294330 - SPY-X: A Study to Assess the Feasibility of Using SPY Alone for Sentinel Node Localization for Melanoma or Breast Cancer Phase 3
Not yet recruiting NCT04930692 - A Prospective Single-center Cohort Study "Preoperative Identification of Sentinel Lymph Nodes Using Contrast-enhanced CT Lymphography in Breast Cancer Patients" N/A
Recruiting NCT03749707 - HPV in Sentinel Lymph Nodes N/A
Completed NCT03899441 - Multimedia Aid Gynecologic Counseling and Consent N/A
Recruiting NCT04826211 - Axillary Staging in Node Positive Breast Cancer Patients Receiving PST. SNB vs PET/MRI N/A
Not yet recruiting NCT06130241 - Sentinel Lymph Node Biopsy After Neoadjuvant Chemotherapy in Initially Node Positive Breast Cancer Patients, Could it Omit Axillary Dissection ? N/A
Recruiting NCT04664582 - Sentinel Lymph Node Biopsy for Cutaneous Squamous Cell Carcinoma of the Head and Neck N/A
Withdrawn NCT04487912 - Dynamics and Tracer Distribution of Tilmanocept in Early Stage Breast Cancer Phase 4
Completed NCT03563781 - SEntine Lymph Node in earLY Ovarian Cancer (SELLY) N/A
Recruiting NCT05623280 - Artificial Intelligence Analysis of Fluorescence Image to Intraoperatively Detect Metastatic Sentinel Lymph Node.
Active, not recruiting NCT05359783 - Sentinel Node Localization and Staging With Low Dose Superparamagnetic Iron Oxide Phase 1/Phase 2
Not yet recruiting NCT04568941 - Comparison Study of Different Tumor Biopsy Method for Sentinel Lymph Node Biopsy in Breast Cancer N/A
Completed NCT03606616 - Prospective Feasibility Study Applying the ACOSOG Z0011 Criteria to Chinese Patients
Recruiting NCT02982148 - Methylene Blue Intradermal Injection for Sentinel Lymph Node Biopsy for Breast Cancer Patients Phase 4
Recruiting NCT06161428 - Optical Guided Sentinel Node Biopsy for Staging of Vulvar Cancer
Completed NCT03900104 - Cervical and Endometrial Injection for Sentinel Lymph Node Detection in Endometrial Cancer N/A